Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Our group and others internationally have previously reported data on the use of low-dose flumazenil administered intravenously for the management of benzodiazepine withdrawal. This paper describes the first reported use of subcutaneous flumazenil infusion in the management of acute benzodiazepine withdrawal. Self-reported withdrawal symptoms and psychological state and anxiety sequelae were collected at baseline and then at intervals to 5 days following initiation of subcutaneous flumazenil infusion. Data indicate that patient subjective benzodiazepine withdrawal symptoms were well managed, with significant reduction in psychological distress seen over the duration of treatment. Perceived difficulty in performing everyday functions was positively correlated with withdrawal severity and improved over treatment. Patients reported high treatment comfort, willingness to undertake a future subsequent treatment using this technique, and willingness to recommend this treatment to a friend. This small proof-of-concept study indicates that subcutaneous flumazenil infusion has excellent tolerability, efficacy and improvement on measures of psychological distress. Given this technique is less invasive and requires fewer staff resources compared with intravenous administration, it may prove a significant asset in the management of benzodiazepine withdrawal.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Those who have never experienced withdrawal symptoms from BZD discontinuation could quit using BZD more easily [62].”
From Benzodiazepines: Uses, Dangers, and Clinical Considerations (2021) · cites this paper as [62]
Citations
Cites
A Brief Measure for Assessing Generalized Anxiety Disorder: The GAD-7
Spitzer, R. L., Kroenke, K., Williams, J. B. W., & Löwe, B. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.10.1092 · Cited by 31,765
KESSLER, R. C., ANDREWS, G., COLPE, L. J., HIRIPI, E., MROCZEK, D. K., NORMAND, S.-L. T., WALTERS, E. E., & ZASLAVSKY, A. M. (2002) · Psychological Medicine · doi:10.1017/s0033291702006074 · Cited by 10,327
The brief symptom inventory: an introductory report.
Derogatis, L. R., & Melisaratos, N. (1983) · Psychological Medicine · doi:10.1017/s0033291700048017 · Cited by 6,650
Interpreting scores on the Kessler Psychological Distress Scale (K10)
Andrews, G., & Slade, T. (2001) · Australian and New Zealand Journal of Public Health · doi:10.1111/j.1467-842x.2001.tb00310.x · Cited by 2,021 · cited 2×
“At baseline 19 of the 20 persons for which K-10 data were available scored above 16 (high-risk category) (Andrews and Slade, 2001), while only seven participants reported such high levels at day 3–5 post-infusion.”
BackgroundLong-term Therapeutic Use of Benzodiazepines: I. Effects of Abrupt Discontinuation
Rickels, K. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810220015002 · Cited by 332 · cited 1×
“Our finding is consistent with those of other researchers (O’Connor et al., 2008; Rickels et al., 1990) on the importance of baseline anxiety as a predictor of benzodiazepine withdrawal severity.”
ResultWithdrawing Benzodiazepines in Primary Care
Lader, M., Tylee, A., & Donoghue, J. (2009) · CNS Drugs · doi:10.2165/0023210-200923010-00002 · Cited by 318 · cited 1×
“Benzodiazepine withdrawal management in primary care commonly involves gradual reduction in benzodiazepine dose, also known as ‘benzodiazepine taper’, with or without concomitant psychological interventions ranging from supportive counselling to cognitive behaviour therapy (Lader et al., 2009).”
BackgroundProtracted withdrawal syndromes from benzodiazepines
Ashton, H. (1991) · Journal of Substance Abuse Treatment · doi:10.1016/0740-5472(91)90023-4 · Cited by 170 · cited 1×
“Most relapse back to regular benzodiazepine use (Ashton, 1991; Basinska et al., 2010; de las Cuevas et al., 2000).”
BackgroundBenzodiazepine dependence and withdrawal: a review of the syndrome and its clinical management
Schweizer, E., & Rickels, K. (1998) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1998.tb05973.x · Cited by 163 · cited 1×
“Patient variables have also been indicated such as higher pretreatment anxiety and depression, personality pathology, panic disorder diagnosis, and history of alcohol/drug abuse (Schweizer and Rickels, 1998).”
BackgroundCuevas, C. D. L., Sanz, E. J., Fuente, J. A. D. L., Padilla, J., & Berenguer, J. C. (2000) · Addiction · doi:10.1046/j.1360-0443.2000.95224511.x · Cited by 153
Hulse, G. K., Morris, N., Arnold-Reed, D., & Tait, R. J. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.130 · Cited by 135 · cited 1×
“Authors Hulse and O’Neil have conducted animal studies on an implantable polylactide microsphere and implant flumazenil formulation similar to the biodegradable naltrexone implant which has been developed and used for the long-term management of heroin dependence (Hulse et al., 2009).”
BackgroundSelf-citation
Research works printed but not linked: 1
- SA Health, 2009, Benzodiazepine equivalents for oral drugs available in Australia
Cited by
Benzodiazepines: Uses, Dangers, and Clinical Considerations
Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021) · Neurology International · doi:10.3390/neurolint13040059 · Cited by 340
“Those who have never experienced withdrawal symptoms from BZD discontinuation could quit using BZD more easily [62].”
MethodBenzodiazepine dependence and its treatment with low dose flumazenil
Hood, S. D., Norman, A., Hince, D. A., Melichar, J. K., & Hulse, G. K. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12023 · Cited by 165
Self-citationMechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients
Trotti, L. M., Saini, P., Koola, C., LaBarbera, V. A., Bliwise, D. L., & Rye, D. B. (2016) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6196 · Cited by 65
Metadata
- Authors
- Hulse, G., O’Neil, G., Morris, N., Bennett, K., Norman, A., & Hood, S.
- Affiliations
- The University of Western Australia (AU)
- Australian Medical Procedures Research Foundation (AMPRF), Perth, Australia
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2012-05-16
- Volume
- 27
- Issue
- 2
- Pages
- 222-227
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W1971774209
- Cited by
- 27
- References
- 22
- Citations by year
- 2026: 1 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 1 · 2017: 2 · 2016: 4 · 2015: 3 · 2014: 2 · 2013: 1 · 2012: 1
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- Topics
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Emergency Medicine › Poisoning and overdose treatments
- Health Sciences › Medicine › Clinical Neurology › Alcoholism and Thiamine Deficiency
- Keywords
- benzodiazepine withdrawal, flumazenil, withdrawal symptoms, psychological distress, anxiety, patient satisfaction, treatment tolerability, benzodiazepine dependence
- MeSH terms
- Adult, Aged, Anxiety Disorders, Benzodiazepines, Female, Flumazenil, Humans, Male, Middle Aged, Substance Withdrawal Syndrome, Patient Satisfaction, Infusions, Subcutaneous
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series. https://app.cochat.ai/papers/10.1177/0269881112446532
- The paper
- Hulse, G., O’Neil, G., Morris, N., Bennett, K., Norman, A., & Hood, S. (2013). Withdrawal and psychological sequelae, and patient satisfaction associated with subcutaneous flumazenil infusion for the management of benzodiazepine withdrawal: a case series. Journal of Psychopharmacology. https://doi.org/10.1177/0269881112446532
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.